Published in Saudi J Ophthalmol on May 27, 2010
Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J Exp Med (2001) 2.22
Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol (2009) 1.18
Fine needle diathermy occlusion of corneal vessels. Invest Ophthalmol Vis Sci (2000) 1.13
Photodynamic therapy of corneal neovascularization with verteporfin. Cornea (2003) 1.07
Photodynamic therapy with verteporfin for corneal neovascularization. Am J Ophthalmol (2007) 1.07
Efficacy of topical bevacizumab for inhibiting growth of impending recurrent pterygium. Curr Eye Res (2010) 1.02
Corneal allograft rejection: risk factors, diagnosis, prevention, and treatment. Indian J Ophthalmol (1999) 1.01
Effect of subconjunctival bevacizumab on primary pterygium. Cornea (2009) 0.98
Angiostatic activity of steroids in the chick embryo CAM and rabbit cornea models of neovascularization. J Ocul Pharmacol Ther (1999) 0.97
Corneal neovascularization induced by xenografts or chemical cautery. Inhibition by cyclosporin A. Invest Ophthalmol Vis Sci (1997) 0.96
Avastin use in high risk corneal transplantation. Graefes Arch Clin Exp Ophthalmol (2009) 0.95
Steroid inhibition of limbal blood and lymphatic vascular cell growth. Curr Eye Res (1995) 0.88
[Topical inhibition of angiogenesis at the cornea. Safety and efficacy]. Ophthalmologe (2009) 0.87
Laser photocoagulation of feeder vessels in lipid keratopathy. Ophthalmic Surg (1986) 0.86
The Boston Ocular Surface Prosthesis as a novel drug delivery system for bevacizumab. Semin Ophthalmol (2009) 0.81
[Beta-ray therapy of corneal vascularization after keratoplasty]. Klin Monbl Augenheilkd (1972) 0.79
Update on sympathetic ophthalmia. Middle East Afr J Ophthalmol (2012) 1.04